---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021008"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:40:30.869557+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lipocine Q3 net loss widens to $3.2M; cash drops to $15.1M; PPD trial on track

## Summary
- Net loss of $3.2M ($0.59/sh) vs $2.2M loss ($0.44/sh) in Q3 2024.
- Cash & investments $15.1M at Sep 30, 2025, down from $21.6M at Dec 31, 2024.
- R&D spend $2.7M (+69% YoY) driven by LPCN 1154 Phase 3 PPD trial; top-line data expected Q2 2026.
- TLANDO royalty revenue $115k; nine-month license revenue $500k vs $7.5M prior year from Verity deal.
- LPCN 2101 abstracts accepted for AES meeting Dec 5-9; exploring partnerships for multiple assets.

## SEC filing metadata
- accession: 0001493152-25-021008
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225021008/0001493152-25-021008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225021008/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021008
- JSON: https://secwatch.observer/filing/0001493152-25-021008.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.